A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular Disease

Inclusion Criteria:

• Adult participants ≥ 18 years of age.

• Participants or participant's legally authorized representative has providedinformed consent to participate in this study.

• Participants who meet one of the following:

• Prescribed Repatha® in addition to an existing SOC treatment according to localguidelines and approved label.

OR

• Already received SOC treatment prior to enrollment.

• Participants with ANY of the following.

• Diagnosis of MI OR stroke within 2 years before enrollment.

• 2 MIs OR ≥ 2 strokes OR (≥ 1 MI AND ≥ 1 stroke) any time before enrollment.

• Diagnosis of (MI OR stroke) AND diabetes.

• Diagnosis of (MI OR stroke) AND documented multivessel disease (defined as > 50%stenosis of ≥ 2 major coronary arteries on coronary angiography or coronary arterycontrast enhanced computed tomography).

• Diagnosis of symptomatic peripheral arterial disease.

• Most recent fasting LDL-C ≥ 70 mg/dL (≥ 1.8 mmol/L) or nonhigh-density lipoproteincholesterol (non-HDL-C) ≥ 100 mg/dL (≥ 2.6 mmol/L) within 6 months prior toenrollment.

• Most recent fasting triglycerides ≤ 400 mg/dL (≤ 4.5 mmol/L) within 6 months priorto enrollment.

Exclusion Criteria:

• Stroke within past 1 month.

• Known hemorrhagic stroke at any time.

• Stroke due to thromboembolic event.

• Any prior use of Repatha® or other proprotein convertase subtilisin/kexin type 9inhibition treatments within past 6 months prior to enrollment.

• Participants currently enrolled in another study involving any investigationalprocedure, device or drug.

• Participants prescribed Repatha® with a history of severe hypersensitivity orallergy to any subsidiary.